PATENT CLAIM ANALYSIS

Application Number: 16228084
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["424", "139100"]

Abstract:
Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.

Claim (Index 83):
The method of  claim 80 , further comprising administering the antibody in combination with a second therapeutic agent, which is optionally an immunotherapy or a cancer vaccine, wherein the immunotherapy optionally comprises a PD-1 therapy and/or an ICOS therapy.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 98.0
- Lexical Diversity: 1.16667
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15696972', '15451275', '15545871', '15451280', '12906041']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7436907629540132
- 35 USC 102 Novelty (BERT): 0.5350530717145237
- Combined Prediction Score: 0.7228269938300642
- Mean Citation Score: 367.832702
- Max Citation Score: 375.92844
- Similarity Product: 227.5361559963084

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test